Reduced Vaccine Response to HZ/su in SLE
NCT07636044 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80
Last updated 2026-06-09
Summary
The goal of this observational study is to compare the vaccine response to the 2 doses of the adjuvanted herpes zoster subunit vaccine(HZ/su, "Shingrix") in patients with SLE and the age-, sex-, ethnicity-matched controls without autoimmune disease.
Conditions
- Vaccine Reaction
- Zoster
- Systemic Lupus Erythematosus
Sponsors & Collaborators
-
Seoul National University Hospital
lead OTHER
Eligibility
- Min Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-10-01
- Primary Completion
- 2030-10-01
- Completion
- 2030-10-01
Countries
- South Korea
Study Locations
More Related Trials
-
Zostavax in Systemic Lupus Erythematosus
NCT01474720 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus
NCT03618056 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
NCT01196091 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus
NCT07299422 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of LY3361237 in Participants With Systemic Lupus Erythematosus
NCT03933943 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus
NCT00962832 ·Status: COMPLETED ·Phase: PHASE2
-
Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus
NCT01405196 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus
NCT06238531 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
NCT01205438 ·Status: COMPLETED ·Phase: PHASE3
-
To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus
NCT07447986 ·Status: RECRUITING ·Phase: PHASE2
-
The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE
NCT07306585 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Safety of Administering Isoniazid to SLE Patients to Prevent TB
NCT06618573 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)
NCT02885610 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus
NCT05155345 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus
NCT06530849 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
NCT02265744 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)
NCT02660944 ·Status: COMPLETED ·Phase: PHASE2
-
BLYS and IFN in SLE
NCT00611611 ·Status: COMPLETED
-
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of SHR-2173 in Patients With Systemic Lupus Erythematosus
NCT06955598 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE
NCT06015230 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)
NCT00539838 ·Status: TERMINATED ·Phase: PHASE3
-
SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus
NCT06144710 ·Status: COMPLETED ·Phase: PHASE1
-
Auto-immunity in Lupus Patients After Influenza Vaccine
NCT01072734 ·Status: COMPLETED ·Phase: PHASE2
-
JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)
NCT06675422 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease
NCT00624351 ·Status: COMPLETED ·Phase: PHASE2